Can AI really replace pathologists ? Read @RunjanChetty & Dr Kenneth Fleming's take on this controversial question in this pertinent editorial piece from the JCP! bit.ly/4ds0BqN

Pancreatic FNA. Would you believe that these are synthetic images?

Read this editorial titled "Extranodal extension in head and neck cancer: why HN-CLEAR matters and what still needs proof" by the authors - Dr Vikram Deshpande, Dr Munita Bal for an indepth understanding and clarity. Link to the editorial bit.ly/4whlTyk

From adaptor protein to oncogenic driver. A leucine-to-proline substitution at codon 265 (L265P) transforms MYD88 from a tightly regulated signalling adaptor into a constitutively active driver of lymphoma. The result? - Persistent NF-κB activation - Enhanced B-cell survival - Uncontrolled proliferation How does a single molecular alteration reshape an entire signalling network? Read the full Gene of the Month article to see how MYD88 became one of the most important biomarkers in lymphoid malignancies: bit.ly/4o94W5b

June issue is live ! From AI in pathology to evolving molecular insights, this issue spans the future and fundamentals of diagnostic practice. 🔍 Editor’s Choice: MYD88 gene and protein — molecular architecture, signalling pathways, and clinical implications in lymphoid malignancies. Also featuring: • AI triage in duodenal biopsies • Keratin 7 patterns in MASLD • CD103 T cells as metastatic markers • Testicular biopsy heterogeneity in infertility A strong mix of innovation, diagnostics, and translational relevance. #Pathology #DigitalPathology #MedEd #JCP

Better test ≠ better system. This study shows that active B12: 🔍 Classifies more patients as deficiency unlikely 🔍 Reduces the grey “indeterminate” zone Here’s the catch: 💸 It comes at a significantly higher cost ~26× more expensive ! 💡 Take-home: Better diagnostics don’t exist in isolation. They live in real systems, with cost, access, and scale. A great read if you’re thinking about lab medicine: bit.ly/4uVvOI6. #Pathology #LabMedicine #JCP

What’s inside the latest issue of JCP? From evolving diagnostic dilemmas to rare case insights, the May 2026 issue brings together key reads across pathology. Open Access Highlight: Autoimmune conditions & CMML outcomes. If you read one paper today, make it this one! #Pathology #HemePath #OncPath #OpenAccess #JCP #MedTwitter

Check out this paper on ELOC-mutant renal cell carcinoma highlighting the practical diagnostic features and differential considerations by the authors - Meifang Lin, Chuncheng Chen, Shujing Guo, Yue Wu, Fenglian Lin, Xin Ding. Link to the article bit.ly/4te1RSj

Read this editorial titled "Extranodal extension in head and neck cancer: why HN-CLEAR matters and what still needs proof" by the authors - Dr Vikram Deshpande, Dr Munita Bal for an indepth understanding and clarity. Link to the editorial bit.ly/4whlTyk

International Consensus Guidelines for Diagnostic Criteria & Checklist for Future Studies for Minimally Invasive Carcinoma ex Pleomorphic Adenoma: HN CLEAR Initiative Beadle et al rdcu.be/fdSmw #HeadNeckPathol #HNPJ #HeadandNeckPath #Pathology #ENTPath #PathologyTweet

🔊 Our April issue is out now folks! Here are the highlights: ✒️ Editors choice: Histological reporting of locally excised pT1 colorectal cancer in the English Bowel Cancer Screening Programme ⭐ Synaptophysin expression in SMARCA4-deficient undifferentiated carcinoma of the esohagus - A potential pitfall ⭐ ELOC-mutant RCCs - Diagnostic features & Tips for diagnosis ⭐ Pan-TRK IHC in peripheral nerve sheath tumours - Does it truly indicate NTRK rearrangements ? ⭐ Review article: Patient safety in AI-powered diagnostic pathology ✒️ And don't forget to check two excellent editorials by @Vik_deshpandeMD and @mun_mm on - HN-CLEAR consensus for ENE in H&N cancers: bit.ly/4bGKzXg - Advancing the diagnosis of IgG4-related ophthalmic disease: a critical appraisal of current criteria: bit.ly/4sqaI3P

Check out this paper - "High upgrade rate to invasive carcinoma makes subclassification of papillary carcinoma of the breast in core needle biopsy unnecessary" by Di Ai, Abdulwahab M Ewaz, Kevin Van Smaalen, and Xiaoxian Li. Here is the link bit.ly/4skr9OA

WHO-HAEM5 didn’t just rename entities: it reshaped B-cell neoplasm classification. Key updates across small and aggressive B-cell lymphomas highlighted here. More details here: bit.ly/3PIpHHM

EBV-Positive Burkitt Lymphoma Arising in CLL/SLL: A Case Report Linked Here: bit.ly/4kUwaLB

Intraductal Salivary Gland Neoplasms of the Oral Cavity: A Retrospective Case Series with Emphasis on Newly Described Entities H Alshuaibi, S Neduvanchery, SG Fitzpatrick, et. al. rdcu.be/e2mok #HeadNeckPathol #HNPJ #HeadandNeckPath #Pathology #ENTPath #PathologyTweet

An Introduction to Pathology Foundation Models Brandon Veremis, Shengjia Chen & Gabriele Campanella rdcu.be/e2mbi #HeadNeckPathol #HNPJ #HeadandNeckPath #Pathology #ENTPath #PathologyTweet

Contemplating the Face of the Future of Oral Pathology Practice Adam B. Walters rdcu.be/e2meb #HeadNeckPathol #HNPJ #HeadandNeckPath #Pathology #ENTPath #PathologyTweet

Over the weekend, I had the privilege of attending the inaugural meeting of the GI Pathology Society of India—an outstanding event that, I suspect, will soon become a major force in education, research, and outreach in gastrointestinal pathology. What stayed with me most, however, was how often the conversation returned to the WHO Blue Books and their limited relevance in low- and middle-income countries. Colleagues repeatedly came up to me to say they shared the same concern: in their current form, these classifications do not reflect the realities of practice in countries like India. That matters. When pathologists working at enormous scale feel unseen by the very system that claims to set global standards, the problem is no longer merely technical; it is structural. By underrepresenting Indian and other LMIC pathologists, the WHO weakens the legitimacy and usefulness of its own classifications. The irony is unmistakable: a system designed as a global standard remains disproportionately shaped by perspectives from settings far removed from where most patients actually live and receive care.

🌟Claudin 18.2🌟 Murtazaalieva G, Baldwin A, Fassan M, Deshpande V. Claudin 18.2 in cancer research and treatment: a pathologist's perspective. J Clin Pathol. 2025 Dec 17:jcp-2025-210328. doi: 10.1136/jcp-2025-210328. Epub ahead of print. PMID: 41407541.

when not to use the term)New paper alert! Our work on colonic intramucosal adenocarcinoma (when not to use the term) is now online in @JClinPath ahead of print. Quick video walkthrough of the key points. #PathTwitter #GIPath #IMCA #Pathology